cyclosporine was successful in 75% of patients in treating frequent relapses. Mean time to achieve remission was 3.2 months. Overall Tacrolimus was successful in 77% of patients in treating frequent relapses. Mean time to achieve remission was 2.1 months. Out of 15 patients with steroid resistant nephrotic syndrome, 3 patients treated with cyclosporine, 1 achieved partial remission and still continued on CSA where as 2 patients did not respond. Time to achieve remission was 5 months. 2 patients resistant to cyclosporine and 12 steroid resistant patients were treated with tacrolimus (total 14 patients). 11 of 14 (79%) patients achieved complete remission and 2(14%) achieved partial remission. Mean time to achieve remission was 2.5 months. In SRNS patients, tacrolimus was more effective than cyclosporine and was also effective in 1 pt resistant to CSA. Conclusions: In frequent relapsing nephrotic syndrome patients, both cyclosporine and tacrolimus has comparable efficacy and no significant difference. Overall success rate (CR, PR and infrequent relapses) was 75% and 77% respectively. In steroid resistant nephrotic syndrome patients, tacrolimus was more effective than cyclosporine and also effective in CSA resistant patients. Combined remission rate (CR & PR) of 93% with tacrolimus as compare to only 33% with cyclosporine was achieved in SRNS. Late steroid resistance is associated with better response to CNI therapy as compared to primary CNI resistance. Introduction: Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) with persistent proteinuria >1 g/day despite 3-6 months of supportive care and eGFR >50 ml/min/1.73m2. Whether the benefits of this treatment extend to patients with an eGFR<50 ml/min/1.73m2 is unclear. We retrospectively studied the effect of steroids on disease progression and proteinuria in IgA N patients with eGFR < 50ml/min/1.73m2 compared to those with >50ml/min/1.73m2. Methods: A cohort of biopsy proven primary IgA N diagnosed between March 2010 and February 2015 who received oral corticosteroids and followed-up for a minimum of six months were included. They were categorized into two groups as per eGFR. (Group 1 -eGFR>50 ml/min/1.73m2, Group 2 -eGFR < 50ml/min/ 1.73m2). Baseline characteristics were compared between the groups. The eGFR and urine protein creatinine ratio (UPCR) were followed up at entry time, 6 months, 12 months and at the end of follow-up. Outcomes studied were change in eGFR, proteinuria and progression to end stage renal disease (ESRD). Statistical analysis was done using SPSS version 16. Results: Out of 44 patients, 23(52%) had eGFR< 50 ml/min/1.73m2 (Group1) and 21(48%) had eGFR >50ml/min/1.73m2 (Group 2). The baseline clinical, histopathological, and treatment characteristics of both the groups are shown in table 1. At the end of follow-up, similar reduction of proteinuria (UPCR) (p-0.62) was seen in both the groups. But there was significant difference in change in median eGFR/month (p-0.004) ( Table 2) . Patients in Group 2 had a median fall in eGFR of -0.46 ml/min/1.73m2 / month, whereas Group 1 had an increase in median eGFR by +0.38ml/min/1.73m2/ month (Table 2) . One in each group has reached CKD stage 5(p-0.73). Limitations in our study were retrospective in nature, small cohort and short duration of follow-up. Conclusions: Addition of corticosteroids to conservative treatment in IgA N patients with initial eGFR<50 ml/min/1.73m2 seems to reduce proteinuria but not beneficial in preventing progression of disease as compared to patients with higher eGFR (>50ml/ min/ 1.73m2). However we need large prospective randomized control trials with long term follow-up to confirm role of steroids in this subset of IgA N. Kidney International Reports (2016) 1, S1-S22 S13
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